Alzheimer's biotech Cortexyme sets terms for $75 million IPO
Cortexyme, which is developing a novel therapy for Alzheimer's disease, announced terms for its IPO on Monday.
The South San Francisco, CA-based company plans to raise $75 million by offering 4.4 million shares at a price range of $16 to $18. Insiders intend to purchase $35 million worth of shares in the offering. At the midpoint of the proposed range, Cortexyme would command a fully diluted market value of $476 million.
Cortexyme was founded in 2012 and plans to list on the Nasdaq under the symbol CRTX. BofA Merrill Lynch and Credit Suisse are the joint bookrunners on the deal. It is expected to price during the week of May 6, 2019.
The article Alzheimer's biotech Cortexyme sets terms for $75 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO), Renaissance International ETF (symbol: IPOS), or separately managed institutional accounts may have investments in securities of companies mentioned.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
- US IPO Week Ahead: The IPO market shutdown continues with another quiet week
- Blank check IPOs bounce: All 13 of the year's SPACs trade below $10 redemption value
- China's WiMi Hologram ups ADS offering, cuts range on $33 million US IPO
- US IPO Week Ahead: 1 Chinese hologram company takes on a tough IPO market to close out March